AwesomeCapital
Search This Blog
Wednesday, January 8, 2025
Catalyst Settles FIRDAPSE® (amifampridine) Patent Litigation with Teva
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035
https://www.globenewswire.com/news-release/2025/01/08/3006570/13009/en/Catalyst-Pharmaceuticals-Announces-Settlement-of-FIRDAPSE-amifampridine-Patent-Litigation-with-Teva-Pharmaceuticals.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.